**Response to Reviewers**

    In the text below, suggestions and recommendations are given.  
1. From the FTIR analysis, it could not be clearly visible wheater there were some interaction between polymer matrix and drug. Is there shifting of any characteristic peaks after drug encapsulation?  
Also, the authors are supposed to disccus about the physical state of drug after encapsulation. Is drug encapsulated in an amorphous or crystalline form? Please, correlate these findings with XRD analysis results.

**Responses for Reviewer A**

There is no shifting of any characteristic peaks after drug encapsulation. Practically, the same absorption bands appeared in the microspheres spectrum after drug encapsulation. The drug is encapsulated in crystalline form. The IR spectra (Figure 2) did not show any new bands, so, on the basis of this analysis, the incorporation of 2-aminobenzothiazole did not cause any chemical reaction. See the pages 8 and 9 of the manuscript. Further, XRD analysis (Figure 3) showed also crystalline character of pure 2-ABZT; in fact, The X‐ray diffraction patterns of microspheres samples showed some characteristic peaks of 2-ABZT but with low intensities, indicating the presence of the encapsulated drug in the crystalline form; then the X‐ray diffraction analysis confirmed the FTIR analysis. See the pages 9 and 10 of the manuscript, the text was added in red color.

**Responses for Reviewer B**

2. It is strongly recommended to the authors to check the papers related to drug release systems in order to provide the correctly presented graph of in vitro drug release. There is no need to show two curves for one polymer matrix done in duplicates. It is common to present the average values with the standard deviations.

**Response:**

The graphs of in vitro drug release were correctly presented. See the Fig. 4 in the page 11 of the manuscript.